Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-21, Stock:PFE, The news for the past five days is as follows:
2018-08-14: NEWS1: Pfizer Expected to Report Robust EPS Rise in Fiscal 2018.NEWS2: How IBM’s Global Business Services Unit Is Doing.NEWS3: Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018.
2018-08-15: NEWS1: FANG Stocks Take Heat As Distribution Hits Nasdaq; Netflix Slumps 3.5%.NEWS2: A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity.NEWS3: Buy Stocks That Are Down, Not Up, Here.NEWS4: 3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug.NEWS5: 3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug.NEWS6: Allergan plc. (AGN) Ex-Dividend Date Scheduled for August 16, 2018.NEWS7: Allergan plc. (AGN) Ex-Dividend Date Scheduled for August 16, 2018.NEWS8: 3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug.NEWS9: Novo Nordisk’s Biopharmaceuticals Segment: An Update.NEWS10: What's Next for Spark Therapeutics.NEWS11: What's Next for Spark Therapeutics.NEWS12: What&apos;s Next for Spark Therapeutics.NEWS13: ViiV Healthcare: ATLAS Study Meets Primary Endpoint - Quick Facts.NEWS14: ViiV Healthcare: ATLAS Study Meets Primary Endpoint - Quick Facts.
2018-08-16: NEWS1: Cramer throws out this tech stock to diversify portfolio.NEWS2: FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%.NEWS3: Health Care Sector Update for 08/16/2018: TEVA, REGN, PFE, MDT, SNY.NEWS4: Health Care Sector Update for 08/16/2018: TEVA, REGN, PFE, MDT, SNY.NEWS5: Health Care Sector Update for 08/16/2018: TEVA,REGN,PFE,MDT.NEWS6: Health Care Sector Update for 08/16/2018: TEVA,REGN,PFE,MDT.NEWS7: Dow Movers: DIS, WMT.NEWS8: Dow Movers: DIS, WMT.NEWS9: 3 Terrible Reasons to Sell Pfizer Stock.NEWS10: Novo Nordisk A/S (NVO) Ex-Dividend Date Scheduled for August 17, 2018.NEWS11: Novo Nordisk A/S (NVO) Ex-Dividend Date Scheduled for August 17, 2018.NEWS12: 3 Terrible Reasons to Sell Pfizer Stock.NEWS13: MYL Stock Down ~3% since Its Q2 2018 Results on August 8.NEWS14: Should Gilead Be Worried About This New Monthly HIV Medication?.NEWS15: Should Gilead Be Worried About This New Monthly HIV Medication?.NEWS16: Most Analysts Are Optimistic about Vertex Pharmaceuticals.NEWS17: See what the IHS Markit Score report has to say about Pfizer Inc..NEWS18: Stocks making the biggest moves premarket: WMT, JD, JCP, BA, CSCO & more.NEWS19: Should Gilead Be Worried About This New Monthly HIV Medication?.NEWS20: [$$] Pfizer, BioNTech in $425 Million Flu Vaccine Collaboration.NEWS21: BioNTech, Pfizer To Develop MRNA-based Vaccines For Prevention Of Influenza.NEWS22: BioNTech, Pfizer To Develop MRNA-based Vaccines For Prevention Of Influenza.NEWS23: [$$] Teva shares climb after FDA approves its generic EpiPen.NEWS24: [$$] Teva climbs higher after FDA approves its generic EpiPen.NEWS25: Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance.NEWS26: Pfizer bets on biotech flu vaccine in $425 mln BioNTech alliance.
2018-08-17: NEWS1: 2 Reasons Alnylam Stock Fell on a Landmark Drug Approval.NEWS2: 2 Reasons Alnylam Stock Fell on a Landmark Drug Approval.NEWS3: 2 Reasons Alnylam Stock Fell on a Landmark Drug Approval.NEWS4: Retailer Breaks Out As This Dow Jones Stock Is A New Emerging Winner.NEWS5: 3 Tough-Luck Tumbles in Healthcare: Are They Buys?.NEWS6: 3 Tough-Luck Tumbles in Healthcare: Are They Buys?.NEWS7: Pfizer, at Highest Price in a Decade, May Fall 10%.NEWS8: 3 Tough-Luck Tumbles in Healthcare: Are They Buys?.NEWS9: Company News For Aug 17, 2018.NEWS10: Company News For Aug 17, 2018.NEWS11: Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic.NEWS12: Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic.NEWS13: Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead.NEWS14: Lifesaving EpiPen Device Still Out of Stock at Many Pharmacies.NEWS15: Lifesaving EpiPen Device Still Out of Stock at Many Pharmacies.NEWS16: Life-Saving EpiPen Device Still Out of Stock at Many Pharmacies.NEWS17: Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic.NEWS18: Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen.NEWS19: Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen.NEWS20: Company News For Aug 17, 2018.NEWS21: If I Had to Buy 1 Stock in August, It Would Be This One.NEWS22: If I Had to Buy 1 Stock in August, It Would Be This One.NEWS23: EpiPen shortage has parents struggling during back-to-school season.NEWS24: EpiPen shortage has parents struggling during back-to-school season.NEWS25: See what the IHS Markit Score report has to say about Pfizer Inc..NEWS26: If I Had to Buy 1 Stock in August, It Would Be This One.NEWS27: Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study.NEWS28: Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study.NEWS29: Glaxo, J&J&apos;s Dual Drug HIV Regimen Succeeds in Phase III Study.NEWS30: New Drugs Approved In July.NEWS31: New Drugs Approved In July.
2018-08-20: NEWS1: Amgen’s Product Performance in Q2 2018.NEWS2: Roche's Lung Cancer Drug Alecensa Gets Approval in China.NEWS3: Roche's Lung Cancer Drug Alecensa Gets Approval in China.NEWS4: Drugmakers Extend Summer Rally as Markets Regain Footing.NEWS5: XLV, JNJ, UNH, PFE: Large Inflows Detected at ETF.NEWS6: XLV, JNJ, UNH, PFE: Large Inflows Detected at ETF.NEWS7: Array BioPharma’s Immuno-Oncology Collaborations: Trial Update.NEWS8: Mylan Cuts Its Fiscal 2018 Guidance, Citing US Market Challenges.NEWS9: Pfizer Invites Public to View and Listen to Webcast of August 27 Conference Call with Analysts and Investors to Review Tafamidis Data Presentation at ESC Congress 2018.NEWS10: 3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro.NEWS11: 3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro.NEWS12: Pfizer Reaches Analyst Target Price.NEWS13: Pfizer Reaches Analyst Target Price.NEWS14: Mylan Has a Strong Balance Sheet despite Weak Q2 Performance.NEWS15: 3 Things Alnylam&apos;s Management Wants Investors to Know About the Launch of Onpattro.NEWS16: Non-Opioid Pain Therapy Market Opportunity for Teva.NEWS17: Allergan’s US Specialized Therapeutics Segment in Q2 2018.

Answer: Decrease